Bruker Corp Stock Price, News & Analysis

Bruker Corporation (Nasdaq: BRKR) has announced the pricing of its public offering of $600 million of 6.375% Mandatory Convertible Preferred Stock, Series A. The offering includes 2.4 million shares at a liquidation preference of $250 per share, with a 30-day option for underwriters to purchase an additional $90 million.

The preferred stock will automatically convert to common stock on September 1, 2028, with conversion rates between 6.9534 and 8.5179 shares of common stock per preferred share. Dividends will be paid quarterly at a 6.375% annual rate starting December 1, 2025. The company expects net proceeds of approximately $582 million, which will be used to repay various term loans and credit facilities.

Bruker Corporation (Nasdaq: BRKR) has announced a public offering of $600 million in Mandatory Convertible Preferred Stock, Series A. The offering includes 2.4 million shares with a liquidation preference of $250 per share, with an additional 30-day option for underwriters to purchase up to $90 million more shares.

The company plans to use the proceeds to strengthen its balance sheet by repaying various loans, including a term loan due December 2026, outstanding borrowings under its 2024 revolving credit agreement, and part of a term loan due March 2027. The preferred stock will automatically convert to common stock around September 1, 2028, unless converted earlier by holders.

Bruker Corporation (Nasdaq: BRKR) has announced a quarterly cash dividend of $0.05 per share on its common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. This announcement reflects the company's continued commitment to returning value to shareholders through regular dividend payments.

Bruker Corporation (Nasdaq: BRKR) has secured multiple contracts worth over $27 million in 2025 for its explosives and chemical trace detection solutions. The company announced significant deployments including a seven-year framework agreement with Brussels Airport for 80 ETD units, over 200 units across Scandinavian airports, 74 units in Saudi Arabia, and 17 units at Incheon International Airport.

The contracts also include an order for 500 chemical reconnaissance systems from a Central European country's Ministry of Defense. Bruker's detection portfolio includes DE-tector flex systems for passenger and cargo screening, and RAID-XP and RAPIDplus chemical detection systems for homeland security applications.

Bruker Corporation (Nasdaq: BRKR) reported challenging Q2 2025 financial results with revenues of $797.4 million, down 0.4% year-over-year, and organic revenue declining 7.0%. The company's Q2 2025 GAAP diluted EPS was $0.05, while non-GAAP diluted EPS decreased 38.5% to $0.32.

Facing pressure in US academic, biopharma, and industrial markets, Bruker announced a major cost savings initiative targeting $100-120 million in annual cost reductions by FY 2026. The company updated its FY2025 guidance, now expecting revenues of $3.43-3.50 billion (2-4% growth) and non-GAAP EPS of $1.95-2.05, down from $2.41 in FY 2024.

Despite current challenges, Bruker introduced key innovations in proteomics and metabolomics, including timsOmni, timsMetabo, and timsUltra AIP platforms, while expanding its multiomics solutions through the Biocrates acquisition.

Bruker (Nasdaq: BRKR) released preliminary Q2 2025 results, reporting expected revenue between $795-798 million, representing flat reported revenue year-over-year. The company's non-GAAP organic revenue declined approximately 7% year-over-year, while constant-exchange rate revenue decreased about 3%.

Expected non-GAAP EPS of $0.32-0.34 shows a decline of approximately $0.19 per share year-over-year, including a $0.06 foreign currency headwind. The company noted weak academic demand and softness in the U.S. biopharma market affecting Q2 2025 bookings. Bruker will host its earnings conference call on August 4, 2025, at 8:30 a.m. EDT to discuss these results and ongoing cost actions.

Bruker Corporation (Nasdaq: BRKR) announced the successful delivery and installation of its 15th InSight WLI 3D optical metrology system to a major semiconductor manufacturer. This installation is part of a larger 27-system order for 2025, highlighting growing demand for advanced metrology solutions in AI chip manufacturing.

The company's InSight WLI system provides non-contact, high-resolution 3D optical metrology for advanced packaging measurement requirements, crucial for manufacturing next-generation AI chips. The technology measures key aspects like layer-to-layer alignment, surface topography, and coplanarity to maintain yield and quality in semiconductor production.

Bruker Corporation unveiled strategic innovations at ASMS 2025, highlighting two major developments: the integration of RECIPE's ClinMass and ClinDART assay kits with Bruker's EVOQ DART-TQ+ system for therapeutic drug monitoring and drugs of abuse analysis, and the launch of timsMetabo platform for small molecule analysis. Following its majority investment in RECIPE, Bruker has verified IVDR certified ClinMASS kits for use on the EVOQ DART-TQ+ system. The new timsMetabo platform, built on Bruker's trapped ion mobility spectrometry technology, demonstrates superior performance with 40% more low-mass molecule identification in water samples compared to previous systems. The platform focuses on PFAS detection and environmental monitoring, while RECIPE's integration aims to enable high-throughput, chromatography-free workflows for clinical laboratories.

Bruker Corporation (NASDAQ: BRKR) has acquired biocrates life sciences ag, an Austrian leader in mass spectrometry-based quantitative metabolite and lipid analysis. biocrates specializes in metabolomics kits covering over 1,000+ metabolites from more than 40 metabolite classes, combining innovative sample preparation, metabolite identification, and data analysis. This strategic acquisition enhances Bruker's MS-based metabolomics solutions and supports its expansion into multiomics solutions, following previous acquisitions of PreOmics and Biognosys. The acquisition strengthens Bruker's position in the life sciences, biopharma R&D, and clinical research sectors by providing integrated multiomics capabilities. Financial terms of the acquisition were not disclosed.